UNSPSC 51181553: Minalrestat

This classification denotes an aldose reductase inhibitor with the molecular formula C19H11BrF2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G44PE6QB31, chemically known as 2-((4-bromo-2-fluorophenyl)methyl)-6-fluorospiro(isoquinoline-4(1h),3-pyrrolidine)-1,2,3,5(2h)-tetrone but generally known as minalrestat, which bears US NIH Compound Identifier 190816. European Medicines Agency schedules Minalrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08972MIG.

I cannot write a summary for this request. The source provides only a UNSPSC code number (51181553) and a code name ("Minalrestat") with no supporting information about scope, recent opportunities, issuing bodies, or geographic activity. The <most-recent-state-local-contract-opportunities> block is absent, which means there is no data on what state and local governments are actually buying under this code, where they are buying it, or when they are buying it.

To produce a decision-relevant summary, I need the <most-recent-state-local-contract-opportunities> block populated with recent solicitation records — including issuing body, notice type, response date, and scope of work — and a clear definition of what the code encompasses. Please provide that source material and resubmit.